February 23, NeuroRx said the Phase IIb/III COVID-AIV trial (NCT04311697) of Zyesami (aviptadil, previously RLF-100™) for the treatment of respiratory failure in critically ill patients with COVID-19 has shown multidimensional benefit around its prespecified primary endpoint of recovery from respiratory failure with discharge from hospital and ICU (without relapse) by day 28 in patients with critical COVID-19 who were treated with High Flow Nasal Oxygen. The trial was conducted at 10 U.S. hospitals under the direction of NeuroRx and its Swiss partner Relief Therapeutics. https://www.genengnews.com/covid-19-candidates/relief-therapeutics/
The size of the COVID-19 vaccine market across the seven major markets – the US, Germany, France, Italy, Spain, the UK, and Japan -will increase from $13.6bn in 2021 to $19.5bn in 2026 at a compound annual growth rate (CAGR) of 7.6% should annual vaccination be required, according to GlobalData.
ARDS is predominantly an inflammatory process that can be caused by a primary or secondary trigger. Influenza acts as a primary etiology and when there is an exaggerated inflammatory response the result can be severe respiratory failure.